Freezing Time Prediction of Biologic Formulated Drug Substance Using the Plank Model.

The freezing of biologics has been widely studied from the physical chemistry point of view, for instance in terms of cryo-concentration, excipient crystallization, pH swing, potential protein denaturation, etc. In contrast, considerations on the processing aspects are very limited. For instance, the impact of freezer temperature, container size, freezer load, and freeze chilling capacity on the freezing rate in the most frequent case of freezing in a bottle have not been reported. In this study, the freezing time of either water or buffer solution was measured in various processing conditions. Experimental trials were conducted using containers ranging from 1 to 20 L in two types of freezers: a normal freezer (-30°C set point) and an ultra freezer (-70°C set point). These trials showed that both the container size and the freezer load influenced the freezing times. The current study demonstrated that the use of the well-established Plank model for freezing, coupled with freezer performance characterization, allows the description of the actual freezing kinetics in a very simple and accurate manner. The kinetics can then be modeled to accurately predict both the actual freezer temperature (possibly above the set point) and the freezing time based on freezer load.

Moving to CoPACaPAnA: Implementation of a continuous protein A capture process for antibody applications within an end-to-end single-use GMP manufacturing downstream process.

For the first time to our knowledge the implementation of a continuous protein A capture process for antibody applications (CoPACaPAnA) embedded in an end-to-end single-use 500 L GMP manufacturing downstream process of a multispecific monoclonal antibody (mAb) using a single-use SMB system was conducted. Throughout the last years, a change concerning the pipelines in pharmaceutical industry could be observed, moving to a more heterogeneous portfolio of antibodies, fusion proteins and nanobodies. Trying to adjust purification processes to these new modalities, a higher degree of flexibility and lower operational and capital expenditure is desired. The implementation of single-use equipment is a favored solution for increasing manufacturing agility and it has been demonstrated that continuous processing can be beneficial concerning processing cost and time. Reducing protein A resin resulted in 59% cost reduction for the protein A step, with additional cost reduction also for the intermediate and polishing step due to usage of disposable technology. The downstream process applied here consisted of three chromatography steps that were all conducted on a single-use SMB system, with the capture step being run in continuous mode while intermediate and polishing was conducted in batch mode. Further, two steps dedicated to virus inactivation/ removal and three filtration steps were performed, yielding around 100 g of drug substance going into clinical phase I testing. Therefore, in this study it has been demonstrated that employing a continuous capture within a GMP single-use downstream processing chain is feasible and worthy of consideration among the biotech industry for future application to modality-diverse pipelines.